title: Halting metastasis through CXCR4 inhibition.
abstract: Metastasis occurs when cancer cells leave the primary tumor site and migrate to distant parts of the body. The CXCR4-SDF-1 pathway facilitates this migration, and its expression has become the hallmark of several metastatic cancers. Targeted approaches are currently being developed to inhibit this pathway, and several candidates are now in clinical trials. Continued exploration of CXCR4 inhibitors will generate compounds that have improved activity over current candidates.
authors.affiliation: Department of Chemistry, University of New South Wales, Sydney NSW 2052, Australia. d.ramsey@unsw.edu.au
authors.forename: Deborah M
authors.initials: DM
authors.lastname: Ramsey
authors.forename: Shelli R
authors.initials: SR
authors.lastname: McAlpine
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001596:Benzylamines; D001665:Binding Sites; D054377:Chemokine CXCL12 / Q000037:antagonists & inhibitors / Q000378:metabolism; D002986:Clinical Trials as Topic; D000080027:Cyclams; D006571:Heterocyclic Compounds / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology*; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D010455:Peptides / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D061905:Single-Domain Antibodies / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001596:Benzylamines; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D000080027:Cyclams; D006571:Heterocyclic Compounds; D010455:Peptides; D019718:Receptors, CXCR4; D061905:Single-Domain Antibodies; C088327:plerixafor